IceCure Expands Dutch Footprint with Exclusive Cryoablation Distribution Deal
Event summary
- IceCure Medical signed an exclusive distribution agreement with Scovas Medical for ProSense® cryoablation systems in the Netherlands.
- The deal covers breast cancer and interventional oncology applications, with an initial term and potential for a longer-term agreement.
- The Netherlands is a strategic market due to the ongoing Phase III THERMAC trial, which selected cryoablation for its 94% success rate and 0% complication rate.
- Scovas brings clinical support capabilities and procedural relationships to expand ProSense® adoption in the region.
The big picture
IceCure's deal with Scovas aligns with the growing trend toward minimally invasive, outpatient-friendly oncology procedures. The Netherlands, with its strong interventional radiology expertise and interest in treatment de-escalation, represents a key market for expanding ProSense® adoption. The Phase III THERMAC trial's focus on cryoablation further validates the technology's potential in early-stage breast cancer treatment.
What we're watching
- Clinical Validation
- How the Phase III THERMAC trial results will impact ProSense® adoption in the Netherlands and beyond.
- Market Penetration
- Whether Scovas can effectively expand ProSense® access in a market with strong interventional radiology expertise.
- Regulatory Dynamics
- The pace at which cryoablation gains regulatory approval for broader oncology applications in Europe.
Related topics